ALK (S1206R)
Sign in to save this workspaceALK · Variant type: point · HGVS: p.S1206R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Entrectinib | 100.0% | 0.0% | 93.69 |
| 2 | Gilteritinib | 99.5% | 0.5% | 88.97 |
| 3 | Brigatinib | 99.5% | 0.5% | 82.96 |
| 4 | Alectinib | 99.3% | 0.7% | 95.49 |
| 5 | Repotrectinib | 99.2% | 0.8% | 84.21 |
| 6 | Ceritinib | 98.5% | 1.5% | 95.44 |
| 7 | Crizotinib | 98.1% | 1.9% | 91.39 |
| 8 | Nintedanib | 93.7% | 6.3% | 90.23 |
| 9 | Pralsetinib | 90.3% | 9.7% | 93.43 |
| 10 | Alpelisib | 88.6% | 11.4% | 97.22 |
| 11 | Lorlatinib | 86.9% | 13.1% | 97.24 |
| 12 | Sunitinib | 85.6% | 14.4% | 91.73 |
| 13 | Ruxolitinib | 76.0% | 24.0% | 98.25 |
| 14 | Bosutinib | 74.8% | 25.1% | 87.22 |
| 15 | Pacritinib | 54.1% | 45.9% | 88.64 |
| 16 | Tenalisib | 50.3% | 49.7% | 97.98 |
| 17 | Osimertinib | 50.3% | 49.7% | 97.24 |
| 18 | Cabozantinib | 46.7% | 53.3% | 92.73 |
| 19 | Defactinib | 43.0% | 57.0% | 92.68 |
| 20 | Fostamatinib | 38.3% | 61.7% | 96.74 |
| 21 | Erdafitinib | 34.6% | 65.4% | 95.71 |
| 22 | Baricitinib | 33.9% | 66.1% | 97.99 |
| 23 | Erlotinib | 23.2% | 76.8% | 99.75 |
| 24 | Axitinib | 21.9% | 78.1% | 93.23 |
| 25 | Fedratinib | 20.2% | 79.8% | 96.21 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Entrectinib | 100.0% | 98.8% | +1.2% |
| Gilteritinib | 99.5% | 99.5% | +0.1% |
| Brigatinib | 99.5% | 99.2% | +0.2% |
| Alectinib | 99.3% | 98.6% | +0.7% |
| Repotrectinib | 99.2% | 99.4% | -0.2% |
| Ceritinib | 98.5% | 98.3% | +0.3% |
| Crizotinib | 98.1% | 97.7% | +0.4% |
| Nintedanib | 93.7% | 84.9% | +8.8% |
| Pralsetinib | 90.3% | 82.6% | +7.7% |
| Alpelisib | 88.6% | 80.7% | +7.9% |
| Lorlatinib | 86.9% | 97.2% | -10.3% |
| Sunitinib | 85.6% | 87.7% | -2.1% |
| Ruxolitinib | 76.0% | 52.1% | +23.9% |
| Bosutinib | 74.8% | 75.1% | -0.3% |
| Pacritinib | 54.1% | 55.3% | -1.1% |
| Tenalisib | 50.3% | 45.2% | +5.1% |
| Osimertinib | 50.3% | 80.5% | -30.2% |
| Cabozantinib | 46.7% | — | — |
| Defactinib | 43.0% | — | — |
| Fostamatinib | 38.3% | — | — |
| Erdafitinib | 34.6% | — | — |
| Baricitinib | 33.9% | 46.4% | -12.5% |
| Erlotinib | 23.2% | — | — |
| Axitinib | 21.9% | — | — |
| Fedratinib | 20.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_lung | Lung | |
| anaplastic_large_cell_lymphoma | Blood/Lymphatic System |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.7ms